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Abstract.
PURPOSE: To investigate the effectiveness of outpatient robot-assisted gait training (RAGT) in ambulatory children with spastic
cerebral palsy.
METHODS: Children were randomized to two different intervention sequences within a pragmatic crossover design. They
performed five weeks of RAGT (3 sessions per week) and five weeks of usual care (UC). Dimension E of the Gross Motor Function
Measure-88 (GMFM E) as the primary outcome as well as Dimension D (GMFM D), and timed walking tests were assessed
before and after each treatment sequence and after a 5-week follow-up.
RESULTS: The trial was stopped early because of recruitment problems. We included 16 children with a mean age of 11.3 years
(6.0–15.3 years). GMFM E median (IQR) change scores were −0.7 (−2.8 to 3.5) after RAGT and 0 (−2.4 to 2.4) after UC.
Neither GMFM E nor any secondary outcome measure changed significantly after RAGT or UC, nor were any period, follow-up,
or carry-over effects observable.
CONCLUSIONS: RAGT as a single intervention was not effective in improving walking abilities in the included children. It
should be embedded in a holistic treatment approach, as it cannot cover all aspects relevant to gait. Furthermore, children’s
personalized rehabilitation goals should be carefully monitored with individualized measurement instruments.
Keywords: Child, cerebral palsy, robotics, walking, crossover design, randomized controlled trial
1. Introduction
Cerebral palsy (CP) is one of the most common phys-
ical disabilities, which affects about 2–3 children per
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1,000 live births in Western countries [1]. It involves
multiple dimensions of health. Children with CP are of-
ten restricted regarding independent mobility and daily
walking activity, with one in three not being able to
walk [2]. Thus, improving gait function in these chil-
dren is often one of the main goals of the families and
the rehabilitation team [3,4]. Pediatric neurorehabilita-
tion addresses this goal with various impairment-based
approaches (i.e., focusing on the body structures and
1874-5393/20/$35.00 c© 2020 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License
(CC BY-NC 4.0).
138 C. Ammann-Reiffer et al. / Lessons learned from conducting a pragmatic, randomized, crossover trial
functions of the International Classification of Func-
tioning, Disability and Health: Children and Youth Ver-
sion (ICF-CY)) and more task-specific approaches (i.e.,
focusing on the activity component of the ICF-CY) [5].
A meta-analysis showed a substantial effect of differ-
ent task-specific gait training interventions on walking
speed in children with CP [5]. Additionally, Zwicker
et al. found positive results on various parameters of
the body function (e.g., step length, cadence, and gait
speed) and the activity component of the ICF-CY (e.g.,
Gross Motor Function Measure-88 (GMFM-88) Di-
mension D and E) when summarizing the evidence of
several systematic reviews on different kinds of tread-
mill training in children with neuromotor disorders [6].
New robotic rehabilitation technologies have revo-
lutionized the neurorehabilitation field during the last
15 years and have increasingly been implemented in
the clinical setting [7]. They facilitate prolonged active
training duration with more repetitions in a consistent
movement pattern and provide an attractive and enter-
taining training opportunity due to the implementation
of serious games. Further, the training parameters are
automatically recorded and allow for a better compar-
ison of training intensity across different centers. One
of these rehabilitation robots is the driven gait ortho-
sis Lokomat R© (Hocoma AG, Volketswil, Switzerland),
which enables robot-assisted gait training (RAGT) for
children starting at an early age of approximately five
years [8]. The Lokomat automates gait therapy on a
treadmill by two actuated leg orthoses which are avail-
able in pediatric and adult sizes [8,9]. These orthoses
are individually adapted to the patient’s legs and are
attached with cuffs, while the patient is secured using
a dynamic bodyweight support system with a harness
providing partial bodyweight support. The Lokomat of-
fers many possibilities for variations of training param-
eters, such as leg joints’ range of motion, gait speed,
amount of bodyweight support, and guidance force [10].
Such modern technology raises high expectations in
parents of children with CP regarding gains in their
child’s walking abilities and the development of a gait
pattern comparable to that of non-disabled children [3].
However, it is often a challenge for the therapy team to
meet these expectations appropriately, as scientific evi-
dence in this area shows large deficits. Although studies
have provided evidence on the Lokomat’s feasibility
and safety in pediatric populations [8,11], information
on the optimal frequency and duration of such interven-
tions as well as the intensity and dosage of the train-
ing parameters is sparse. A recent systematic review
concluded that no specific delivery modes for RAGT in
children exist and that evidence of its effectiveness is
still weak and inconsistent [12]. A primary reason for
the weak evidence is that most published results were
derived from uncontrolled single case studies or case
series [8,13–17] and only a few randomized controlled
trials (RCT) have been published [18–22]. However,
performing an RCT in rehabilitation is challenging.
Most of these RCTs showed some methodological lim-
itations. Limitations included the randomization pro-
cedure [18,19], inconsistencies between inclusion cri-
teria and included patient sample [18], a large dropout
rate [19], and severe statistical flaws [20,21].
When we started our RCT in 2009, only the results of
the first uncontrolled single case studies and case series
studies were available. As we were interested in the
effects of RAGT as it is performed in our rehabilitation
center, we applied a pragmatic trial design [23]. This
study design evaluates the effects of an intervention
under the usual everyday real-life conditions in which
it is applied, by keeping aspects such as eligibility cri-
teria of the included patient population, outcome mea-
sures, flexibility of intervention, or therapists’ expertise
as close as possible to everyday life conditions [24].
Accordingly, we chose a 5-week period of RAGT, as
this conforms to the duration and frequency of RAGT
as it is usually provided in the outpatient setting of our
center. We further chose to apply a crossover design,
which enables each child to receive both treatments
in a random order. As each patient can act as his or
her control, and variation within a person is usually
less than between patients, the treatment effect can be
estimated more precisely. With that, it requires only
about half the number of patients needed in a parallel
group design [25]. As pediatric neurorehabilitation is
generally faced with low case numbers, a reduction in
sample size is a favorable factor in this research field.
We, therefore, accepted possible disadvantages of the
crossover design like carry-over or period effects and
longer study duration for the participants and addressed
these statistically.
Thus, this research project aimed to investigate the
effectiveness of RAGT on improvements of functional
gait parameters in ambulatory children with CP in a
pragmatic, randomized crossover trial. We hypothesized
that a 5-week period of RAGT on the Lokomat in an
outpatient setting would be superior concerning the
improvement in gait function when compared to a 5-
week phase of standard treatment in children with a
bilateral spastic CP within a crossover design with a
randomized treatment sequence.
After a study duration of more than eight years (com-
pared to planned four years), we decided to stop the trial
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mainly due to severe recruitment difficulties which we
could not overcome despite several measures that were
taken in the course of the trial. In this article, we report
on the results of the 16 patients we included until study
termination. Further, we address the lessons learned
from our study, on the one hand from the content side
regarding the Lokomat intervention, and on the other
hand regarding methodological choices that potentially
influenced study enrollment.
2. Methods
The study was designed in accordance with the Dec-
laration of Helsinki [26] and the extensions of the CON-
SORT (Consolidated Standards of Reporting Trials)
statement for non-pharmacologic treatment interven-
tions [27] and pragmatic trials [28]. It was approved by
the Ethics Committee Zurich and registered on Clini-
calTrial.gov (NCT00887848).
Written informed consent and assent was obtained
from all the legal guardians and the child by the study
coordinator (C.A.) before participation.
2.1. Design and setting
The methods of this study are outlined in detail in the
published study protocol [23]. In short, the study was
designed as a pragmatic, randomized, crossover trial.
It was carried out in the outpatient setting of the Swiss
Children’s Rehab of the University Children’s Hospi-
tal Zurich in Affoltern am Albis (Switzerland). Later,
the Pediatric Therapy Center of the Reha Rheinfelden
(Switzerland) was added as a second recruiting center.
2.2. Participants
Children aged 6 to 18 years with a bilateral spastic
CP and a Gross Motor Function Classification System
(GMFCS) levels II–IV who were able to walk at least
14 meters with or without walking aids were eligible
for study participation. They had to be able to follow
instructions and communicate pain or discomfort. Ex-
clusion criteria were neuro- or orthopedic surgery on
the lower extremity or trunk within the last six months,
having participated in another Lokomat training regi-
men within the previous six months as well as a change
in concomitant drug therapy within the last four weeks
before or during the study period. Further, children
showing contraindications as outlined in the Lokomat
manufacturer’s manual were excluded.
2.3. Randomization
Children were randomized to two different pre-
specified sequences of interventions. The two inter-
ventions were RAGT as treatment (T) on the Lokomat
on an outpatient basis and usual care as control (C) in
the home environment of the child. A child could be
randomized to a T/C sequence (TC-group) or a C/T/C
sequence (CTC-group). Randomization into the two
groups was performed using a minimization method
with a random factor of 0.9. Minimization facilitates
balancing even small groups in terms of selected patient
factors at all stages of a trial. We included the factors
severity of impairment (GMFCS-levels II and III/IV),
age (6–11 years and 12–18 years) and Botulinum Toxin
A-treatment in the preceding six months (present and
absent). Concealed allocation was ensured by storing
the independently generated randomization list off-site
and requesting information about children’s group allo-
cation by phone or e-mail.
2.4. Intervention
2.4.1. Usual care (C)
Usual care typically consisted of one to two individ-
ual sessions of physiotherapy per week. Each session
lasted 30 to 45 minutes. Additionally, hippotherapy,
circuit training, or occupational therapy could be el-
ements of standard treatment. These therapies, which
were individually customized to the needs of the child,
were mostly implemented in the school setting or in the
child’s home environment. Usual care treatment did not
specifically address gait training but instead consisted
of elements addressing the leg joints’ range of motion,
muscle tone reduction, balance, activities of daily liv-
ing, etc., using the ICF-CY as planning and treatment
framework. Responsibility, planning, and content of
the C-treatment were entirely in the hand of the child’s
therapist in the home environment. Information about
the type, duration, and frequency of all therapies was
documented in a logbook by the parents.
2.4.2. RAGT (T)
RAGT on the Lokomat was applied three times per
week over five consecutive weeks with a maximum
of 45 minutes of effective walking time per session.
RAGT sessions were executed according to published
recommendations [10] by trained and experienced ther-
apists who were used to working with children. Serious
games and other available motivating strategies were
used to increase children’s adherence to the training.
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Fig. 1. Overview of the outcome measures and the measurement time points per group. Children randomized to the CTC-group with the intervention
sequence usual care/robot-assisted gait training (RAGT)/usual care were measured at four different time points within 16 weeks. Children
randomized to the TC-group underwent the intervention sequence RAGT/usual care and were measured at three different time points within
11 weeks. Differences regarding intervention time and numbers of measurement time points were deliberately chosen to reduce the burden on
children and families as much as possible.
Body-weight support, gait speed, training duration, as
well as guidance force of the Lokomat were individu-
ally adjusted according to the child’s abilities and mod-
ified within training sessions and during the course over
time. Standard therapies as described under usual care
could be continued during the RAGT period, but should
not include specific walking training. Type and dosage
of concomitant treatment were recorded in a logbook.
The duration of study participation and number of
assessment time points varied based on group allocation
between 11 weeks with three assessment time points
(TC-group) and 16 weeks with four assessment time
points (CTC-group) (see Fig. 1).
2.5. Outcome measures
2.5.1. Primary outcome measure
We selected the percentage score of the dimension
E of the GMFM-88 (GMFM E) as the primary out-
come measure. The GMFM E assesses walking, run-
ning, and jumping [29] and consists of 24 items, which
are scored on a 4-point ordinal scale. The test was per-
formed without walking aids, regardless of the chil-
dren’s GMFCS-level. A GMFM-certified therapist in-
structed and rated the child. The psychometric proper-
ties of the total GMFM-88 are well explored in children
with CP [30]. Concerning the GMFM E, there is limited
positive evidence for the responsiveness [31].
2.5.2. Secondary outcome measures
We used the percentage score of the dimension D
of the GMFM-88 (GMFM D) to assess the standing
ability. The GMFM D consists of 13 items, which were
tested and scored in the same way as described for
GMFM E. There is also limited positive evidence for
its responsiveness [31], while reliability seems to be
high [32].
Further, a 6-minute walking test (6MinWT) was per-
formed on a 30-meter long corridor with poles at each
end [33]. Evidence for its test-retest reliability is mod-
erate, the minimum detectable change (MDC) is 61.9,
64.0, and 47.4 m for children with a GMFCS level I,
II, and III, respectively [34]. Its responsiveness has not
been established in children with CP so far [31].
Gait speed was assessed with the 10-meter walking
test at self-selected (10MWTss) and fast (10MWTfast)
speeds. Children walked on a 14-meter long track with
orthoses and walking aids usually used in daily life.
Each test was performed twice and the time needed for
the middle 10 meters was measured with a stopwatch.
Evidence for test-retest reliability of the 10MWTfast is
moderate in children with CP [31] and MDCs of 1.7,
4.3, and 17.7s were reported for GMFCS level I, II, and
III, respectively [34].
Further, measures of body function (range of motion,
modified Ashworth scale, and manual muscle tests of
the lower extremities) were evaluated for descriptive
purposes [35,36]. All measurements were performed by
trained physiotherapists who were experienced in work-
ing with children and who followed standardized writ-
ten instructions. Assessors were not blinded regarding
children’s assessment time point.
2.6. Sample size and power calculation
For sample size calculation, we used the PASS Power
Analysis and Sample Size software program (NCSS,
LLC, Kaysville, USA) with a Minimum Important Clin-
ical Difference (MCID) of 3.7%-points in the GMFM
E that was reported by Wang et al. [37] and a standard
deviation of 6.8%-points, which was derived from our
data [13]. With a power of 80% and a significance level
of 5%, it indicated a sample size of 30 to be sufficient
for a 2 × 2 crossover design. We increased this number
to 34 to allow for a predicted dropout rate of about 10%.
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Fig. 2. Overview of the study protocol and the statistical analyses. CTC1, baseline assessment in CTC-group; TC1, baseline assessment in
TC-group; CTC2, intermediate assessment in CTC-group; TC2, intermediate assessment in TC-group; CTC3, end assessment in CTC-group; TC3,
end assessment in TC-group; CTC4, follow-up assessment in CTC-group; ∆C1, change during usual care in CTC-group; ∆C2, change during
usual care in TC-group; ∆C3, change during follow-up in CTC-group; ∆T1, change during robot-assisted gait training in TC-group; ∆T2, change
during robot-assisted gait training in CTC-group.
2.7. Statistical analysis
The statistical analyses were carried out with SPSS
24 (IBM Corporation, New York, USA). Datasets of
all study participants were analyzed on an intention-
to-treat basis. Descriptive statistics are presented for
the clinical characteristics of the study participants and
the quantification of the T- and C-intervention. Treat-
ment effects, period effects as well as follow-up effects
of the two treatment interventions were analyzed with
Wilcoxon signed-rank tests for paired samples, with the
treatment effect being our primary endpoint. Wilcoxon
rank sum tests for unpaired samples were used to de-
termine whether carry-over effects were present [25].
Ninety-five percent confidence intervals are presented
with a two-tailed level of significance set at α < 0.025
for treatment and follow-up effects, and α < 0.05 for
period and carry-over effects. Additionally, we calcu-
lated effect sizes based on the z values of the nonpara-
metric Wilcoxon rank sum tests as r = Z ÷
√
N and
interpreted r > 0.1 as small, r > 0.3 as moderate, and
r > 0.5 as large effect [38,39]. An illustration of all
applied statistical tests is given in Fig. 2.
3. Results
Due to severe recruitment difficulties and the already
prolonged study duration, the study coordinator and the
sponsor (H.v.H.) unanimously decided to close the trial
early. Until trial termination, 16 children and adoles-
cents with a bilateral spastic CP completed the study,
without any dropouts. Descriptive characteristics of the
study participants are presented in Table 1.
Three children belonging to the TC-group had re-
ceived Botulinum Toxin-A treatment into muscles of
the lower extremities within six months before their
study participation.
Regarding the ICF-CY body function level, the me-
dian modified Ashworth score of all children was 0 with
an interquartile range (IQR) of 1. With a median of 3
(IQR: 1), children’s muscle strength was moderate. The
sagittal range of motion values of the lower extremities
are listed in Table 1.
Participants’ treatment adherence was high. Except
for one child, who performed 10 RAGT sessions, all
others completed at least 14 of 15 sessions. Descriptive
parameters regarding dosage and intensity of the RAGT
sessions are listed in Table 2.
In addition to the RAGT sessions, children attended
on average 125 min ± 148 min (0–540 min) of physio-
therapy during the T-intervention, and four children also
continued with their hippotherapy sessions (41 min ±
85 min; 0–300 min). During the C-intervention, physio-
therapy added up to 282 min ± 256 min (0–1’020 min)
and seven children attended hippotherapy (63 min ±
82 min; 0–225 min).
3.1. Primary outcome measure
Results regarding the primary outcome are described
in Table 3. GMFM E percentage scores did not sig-
nificantly increase after the RAGT or after the usual
care period. Neither a treatment effect nor a period,
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Table 1
Descriptive characteristics of the study participants (n = 16)
TC-group CTC-group Total
Gender (n)
Male 6 7 13
Female 2 1 3
GMFCS-level (n)
II 5 4 9
III 2 3 5
IV 1 1 2
Age (years) 11.4 (6.0–15.1) 11.2 (6.1–15.3) 11.3 (6.0–15.3)
Height (cm) 146 (118–178) 142 (110–174) 144 (110–178)
Weight (kg) 41 (24–67) 43 (18–81) 42 (18–81)
Walking aids in everyday life (n)
None 5 4 9
Walker 2 2 4
PA 1 1 2
Wheelchair 0 1 1
Physiotherapy during usual care period
Sessions/week 2 (1–3) 2 (1–3) 2 (1–3)
Minutes/week 90 (45–135) 90 (45–135) 90 (45–135)
Range of motion (◦)
Hip flexion 119 (90–140)
Hip extension −2 (−20–15)
Knee flexion (in 90◦ hip flexion) 145 (110–165)
Knee extension (in 0◦ hip flexion) −2 (−20–15)
Ankle dorsiflexion (in 90◦ knee flexion) 5 (−20–25)
Ankle plantarflexion 45 (20–65)
The number of observations (n) is presented for nominal and ordinal variables. Interval scaled variables
are presented as mean and (range). TC-group, group with treatment-control sequence; CTC-group, group
with control-treatment-control sequence; GMFCS, Gross Motor Function Classification System; PA,
personal assistance.
Table 2
Characteristics of the robot-assisted gait training (RAGT) dosage parameters (averaged over all
training sessions per person)
Mean Standard deviation Minimum-Maximum
RAGT session (n) 14.3 1.2 10–15
Gait speed [m/s] 1.4 0.1 0.5–2.3
Bodyweight support [%] 27 0.8 0–78
Guidance force [%] 94 4 55–100
Session duration [min:sec] 39:45 4:50 15:52–47:00
Distance walked per session [m] 935 159 129–1’636
Distance walked in total [m] 13’519 3’641 2’508–19’843
Table 3
Scores and change scores at different time points, treatment effects and effect sizes of primary and secondary outcome measures
















Median IQR Median IQR
GMFM E [%] 16 53.5 55.6 −0.7 −2.8–3.5 56.3 57.6 0 −2.4–2.4 0.91 −0.02
GMFM D [%] 16 79.5 79.5 0 −2.6–2.6 75.6 79.5 0 −2.6–7.1 0.46 −0.13
6MinWT [m] 14 353 354 11 −13–31 366 353 −0.5 −12–14 0.22 0.23
10WMWTfast [m/s] 13 1.3 1.4 0.1 0.0–0.2 1.4 1.3 0.1 −0.1–0.3 0.70 0.08
10MWTss [m/s] 16 0.9 1.0 0 0.0–0.1 1.0 0.9 0 −0.1–0.1 0.76 −0.05
RAGT, robot-assisted gait training; GMFM D/E, dimension D/E of the Gross Motor Function Measure-88; 6MinWT, 6-minute walk test;
10MWTfast, 10-meter walk test fast speed; 10MWTss, 10-meter walk test self-selected speed.
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Fig. 3. Individual effects of robot-assisted gait training (RAGT) and usual care on Gross Motor Function Measure dimension E (GMFM E) change
scores. The order of the bars reflects the chronological sequence of the treatment. GMFCS, Gross Motor Function Classification Level.
follow-up, or carry-over effect was observable (p =
0.91/0.61/0.75/0.40, respectively). The effect size did
not indicate any effect either. Figure 3 illustrates chil-
dren’s individual GMFM E change scores after RAGT
and usual care.
3.2. Secondary outcome measures
Results of the secondary outcomes are described in
Table 3. None of the secondary outcome measures in-
dicated a significant treatment effect. Effect sizes did
not suggest any effect except for the 6MinWT, which
showed a small effect. No period, follow-up, or carry-
over effects were observed in any of the secondary out-
come measures.
4. Discussion
We investigated the effectiveness of RAGT on im-
proving walking abilities in ambulatory children with
bilateral spastic CP. For this, we used a crossover design
with randomized treatment sequences. We stopped the
trial early, i.e., after more than eight years, when only
16 of the intended 30 patients (34 including dropouts)
finished the protocol, due to recruitment difficulties.
We hypothesized that a 5-week phase of RAGT
would be superior regarding the improvement of walk-
ing abilities when compared to standard treatment with
conventional physiotherapy for the same duration. The
included participants covered a broad spectrum of our
inclusion criteria regarding age, GMFCS-levels, and
walking abilities. After about half of the intended num-
ber of patients finished the protocol, we could not con-
firm this hypothesis. While the lower power may have
hampered statistically significant changes, the effect
sizes of the primary and secondary outcome measures
were not promising.
Existing evidence on the effectiveness of RAGT is
weak and inconsistent [12]. Only four RCTs on RAGT
with the Lokomat in children with CP have been pub-
lished. Druzbicki et al. found no effects on kinematic
and temporospatial gait parameters after four weeks
with 20 sessions of RAGT in children with GMFCS lev-
els II and III [19]. Peri et al. compared different proto-
cols of gait training interventions with RAGT and task-
oriented physiotherapy in 44 children with GMFCS
level I–III [22]. While spatiotemporal and kinematic
gait parameters did not change in any of the protocols,
GMFM E scores improved significantly after 40 RAGT
sessions over ten weeks, as well as after 40 physiother-
apy sessions with standardized gait targeting exercises
for the same period. Improvements (RAGT +3.5%, gait
exercises +3.2%) exceeded the minimal important clin-
ical difference in both groups. The GMFM D also im-
proved considerably in both groups (RAGT +3%, gait
exercises +5%), while the 6MinWT increased only in
the RAGT group (+21 m). However, these results did
not reach statistical significance, and no differences be-
tween the intervention protocols were present. Surpris-
ingly, the protocols with mixed interventions (a com-
bination of 20 RAGT and 20 conventional gait ther-
apy sessions over 4 or 10 weeks) did not reveal any
significant changes at all.
In contrast to the studies described above, the two
RCTs conducted by Wallard et al. (both seem to in-
clude a similar sample of 30 children with spastic CP,
GMFCS-level II) found significant improvements in
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diverse kinematic parameters on the lower and upper
extremities as well as in GMFM D and E scores after 20
sessions of RAGT [20,21]. However, these two studies
prompt various questions regarding the randomization
and concealment of the allocation sequence procedure,
the statistical analyses, and the standardization of the
therapeutic interventions. Further, the clinical relevance
of significant improvements in kinematic parameters of
only a few degrees is at least questionable. The lower-
level design studies on RAGT in children, which did
not include a control group, yielded inconsistent results
regarding improvement in gait speed, gait endurance,
and gross motor function [12].
The results of our study imply that RAGT on an
outpatient basis showed no effects on the investigated
walking abilities in ambulatory children with bilateral
spastic CP. Besides the statistically insignificant results,
the effect sizes, except those of the 6MinWT, did not
indicate any positive results either. Taking our findings
and experiences conducting the trial over the past years
into consideration, we have several points to address.
Some aspects refer to a conceptual level regarding de-
veloping insights into the contents of a rehabilitation
process based on the approach of the ICF-CY. Other
aspects allow more profound methodological insights
into working with a pragmatic trial design in general as
well as in this particular patient group and setting.
Half of the children in our study had previous RAGT
experience and completed their second or third RAGT
phase. Because of our limited sample size, we could
not investigate whether this previous RAGT experience
influenced the outcomes. However, Schroeder et al.
found that repetition of RAGT negatively correlates
with improvement in GMFM scores [40].
Further, evidence exists indicating that the devel-
opment of gross motor function in children with CP
may vary in countries with different health services sys-
tems [41,42]. In Switzerland, as in many other west-
ern European countries and Canada, children with CP
are embedded in a timely and constant rehabilitation
regime. Thus, children in our study already received
a relatively large amount of therapy before their study
participation. Our study results could indicate that in
such situations, RAGT is not intensive or active enough
to promote further improvement in these children.
Concerning the RAGT intervention itself, we tried to
follow a pragmatic approach as much as possible. As
methods and principles of RAGT application and the ac-
companying software changed over the last eight years,
we always aimed to apply the current state-of-the-art
training strategies when performing RAGT. For exam-
ple, we continually implemented the latest Lokomat
software and serious games and adjusted the training
parameters individually to promote active participation
in each child. In regular practice, we do not opt for an
isolated Lokomat training in our center but always com-
bine it with physiotherapy and sports therapy lessons,
focusing on the same individualized goals within a mul-
tidisciplinary rehabilitation approach. These goals are
defined in advance together with the children and par-
ents to cover the areas that are most relevant to each
family and thus mostly concern the activity and partici-
pation component of the ICF-CY.
For the trial, we selected the GMFM E as our pri-
mary outcome, because the GMFM was considered the
gold standard for the evaluation of gross motor function
in children with CP. However, in retrospect, it was not
the most optimal choice for several reasons. Children
with a GMFCS-level III and IV will be able to score
only a few points at most. A substantial change in this
group of children is not to be expected as the test was
performed barefoot and without walking aids (accord-
ing to standard practice in our center). Furthermore,
a pragmatic study approach should reflect the person-
alized rehabilitation goals as best as possible. Thus,
an individualized measurement instrument should be
used as a primary outcome. Such measures will en-
sure that intervention studies examine results relevant
to both the child and family as well as the rehabilitation
team. For this purpose, for example, the Goal Attain-
ment Scale (GAS) or the Canadian Occupational Per-
formance Measure (COPM) may be a promising option,
as the measures quantify the achievement of goals in
a standardized way, while these goals can be individ-
ually set for each child [43–46]. Both tools could be a
feasible option as outcome measures in pediatric reha-
bilitation research [47]: In a recent study, 69% of the
children with CP who had performed a clinical RAGT
intervention had achieved their goals formulated with
the GAS [48]. The COPM was successfully applied as
an outcome measure in the RAGT study of Schroeder et
al., where patient-selected participation goals showed
clinically meaningful improvements [17]. Furthermore,
the COPM score improvements in this study – unlike
the GMFM changes – were not correlated with age,
GMFCS-level, or the number of previous RAGT peri-
ods.
Our training protocol prescribed three RAGT ses-
sions per week throughout five weeks – a frequency and
duration that our team had considered clinically ade-
quate and feasible on an outpatient basis. A 4–5 week
period of 15–20 RAGT sessions also conforms to what
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is usually financed in children with CP by the health
insurances in Switzerland. However, Peri et al. had
adopted 40 therapy sessions within ten weeks in their
groups with significant and clinically meaningful im-
provements, while their group with a mixed protocol
of 20 RAGT and 20 physiotherapy sessions over four
weeks did not improve [22]. The four-week RAGT in-
tervention of Druzbicki et al. did not result in a positive
effect either [19]. The duration of the applied RAGT
period could be a crucial factor for the potential of
improvement in these children.
A crucial methodological lesson learned from this
trial involves the recruitment of study children. Al-
though we took various actions to increase the num-
ber of participating children (prolonged trial duration,
broadened eligibility criteria, expansion from a mono-
to a bi-center trial), we had to recognize that achiev-
ing the calculated sample size within the next one to
three years would have been unattainable. Due to our
intention to explore the effectiveness of RAGT as a
single intervention compared to a usual care approach
(when we started our study, it was standard practice to
compare single therapy interventions with one another),
we decided not to conduct this study in our regular
inpatient setting. In our rehabilitation center, children
stay in the inpatient setting for many weeks and attend
various therapy sessions and school, as it is the only
rehabilitation center specifically for children in Switzer-
land. Offering only RAGT over several weeks instead
of a whole rehabilitation treatment package would not
have been acceptable under these conditions, neither
for the families nor for the treatment team. Although
we also treat children on an outpatient basis in our cen-
ter, this fact, in retrospect, turned out to be one of the
reasons that we were only able to recruit half of the
anticipated children. Most families preferred to arrange
the RAGT period during their child’s school holidays,
to limit the burden on the child as much as possible. The
geographically decentralized location of our center also
brought considerable travel expenses for many families.
These issues reduced the number of participants from
the anticipated ten children to maximally two to three
per year. We expanded the mono- to a bi-center trial
after five years, enlisting the support of the Pediatric
Therapy Center of the Rehabilitation center in Rhein-
felden, the only other center with a pediatric Lokomat
in Switzerland. Unfortunately, despite the local study
coordinator’s high motivation and effort, no single child
could be recruited in this second center.
To avoid such problems, recruitment should focus
as much as possible on the patient population that is
referred to the center for the intervention under study,
thus representing everyday clinical practice. In this way,
logistical challenges, planning efforts, and resources of
participating and executing parties can be kept within a
better manageable and foreseeable range. Moreover, the
research question can be answered within the context it
originated from and not in a more artificial situation.
Unfortunately, discontinuation and nonpublication
of RCTs conducted in children have a high prevalence,
with difficulties in patient recruitment being the most
commonly mentioned reason [49]. Nevertheless, it is
also crucial to publish results of such a trial for several
reasons. In addition to providing at least an indication
regarding the effectiveness of the intervention studied,
researchers can share valuable information about the
problems they were faced with when designing and
conducting their study and the lessons that have been
learned [50].
In general, it should be considered that design choices
towards a more pragmatic or explanatory study de-
sign may affect validity, generalizability, precision, and
feasibility [51]. Currently, the PRECIS-2 tool, which
was developed to support researchers in designing tri-
als, would be a helpful instrument to make informed
decisions about the trials’ position on the pragmatic-
explanatory continuum [52].
We opted for a crossover design because it was re-
garded as the optimal study design for small patient
groups when the study protocol was established. Rec-
ognizing the lessons mentioned above as well as the
present disadvantages of this design (longer trial du-
ration, potential carry-over and period effects, higher
drop-out rates, sophisticated statistical analyses) [53],
other study designs, as n-of-1 trials, single case method-
ology designs, or observational designs, could be con-
sidered as possible alternatives to the chosen crossover
design.
5. Conclusions
The results of our study indicate that 15 sessions of
RAGT within five weeks are not effective in improving
walking abilities in ambulatory children with CP. Our
study adds to the limited evidence of RAGT in children
with CP. However, the results of the current study must
always be interpreted acknowledging that we could
only include half of the targeted number of participants.
We applied RAGT as a single intervention compared
to usual care, in line with the methodological point
of view when designing the study. Our results must
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therefore also be interpreted in this light. Currently,
clinical recommendations are to embed its application
in a holistic treatment with other therapies [10].
An inpatient approach, offering the possibility of
higher RAGT dosages as an add-on therapy element
within an individualized holistic treatment package –
as it is common practice in our center – may be a more
promising, although still challenging strategy to inves-
tigate the effect on walking abilities in children with CP
living in Switzerland. Further high-level design studies
are on the way [54], and until the publication of their
results, we have to monitor each child carefully during
a RAGT intervention to determine whether benefits are
present that justify the efforts and costs of this highly
specialized treatment approach.
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